#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Effects	_
1-2	8-10	of	_
1-3	11-33	dexamphetamine-induced	_
1-4	34-42	dopamine	_
1-5	43-50	release	_
1-6	51-53	on	_
1-7	54-67	resting-state	_
1-8	68-75	network	_
1-9	76-88	connectivity	_
1-10	89-91	in	_
1-11	92-104	recreational	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
1-12	105-116	amphetamine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
1-13	117-122	users	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
1-14	123-126	and	_
1-15	127-134	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-16	135-143	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-17	144-158	Dexamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
1-18	159-160	(	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
1-19	161-166	dAMPH	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
1-20	167-168	)	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
1-21	169-171	is	_
1-22	172-175	not	_
1-23	176-180	only	_
1-24	181-185	used	_
1-25	186-189	for	_
1-26	190-193	the	_
1-27	194-203	treatment	_
1-28	204-206	of	_
1-29	207-216	attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-30	217-224	deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-31	225-238	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-32	239-247	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-33	248-249	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-34	250-254	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-35	255-256	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-36	257-258	,	_
1-37	259-262	but	_
1-38	263-267	also	_
1-39	268-270	as	_
1-40	271-272	a	_
1-41	273-285	recreational	_
1-42	286-290	drug	_
1-43	291-292	.	_

2-1	293-300	Acutely	_
2-2	301-302	,	_
2-3	303-308	dAMPH	_
2-4	309-316	induces	_
2-5	317-324	release	_
2-6	325-327	of	_
2-7	328-341	predominantly	_
2-8	342-350	dopamine	_
2-9	351-352	(	_
2-10	353-355	DA	_
2-11	356-357	)	_
2-12	358-360	in	_
2-13	361-364	the	_
2-14	365-373	striatum	_
2-15	374-375	,	_
2-16	376-379	and	_
2-17	380-382	in	_
2-18	383-386	the	_
2-19	387-393	cortex	_
2-20	394-398	both	_
2-21	399-401	DA	_
2-22	402-405	and	_
2-23	406-419	noradrenaline	_
2-24	420-421	.	_

3-1	422-428	Recent	_
3-2	429-435	animal	_
3-3	436-443	studies	_
3-4	444-448	have	_
3-5	449-454	shown	_
3-6	455-459	that	_
3-7	460-467	chronic	_
3-8	468-473	dAMPH	_
3-9	474-488	administration	_
3-10	489-492	can	_
3-11	493-499	induce	_
3-12	500-507	changes	_
3-13	508-510	in	_
3-14	511-514	the	_
3-15	515-517	DA	_
3-16	518-524	system	_
3-17	525-534	following	_
3-18	535-544	long-term	_
3-19	545-553	exposure	_
3-20	554-555	,	_
3-21	556-558	as	_
3-22	559-568	evidenced	_
3-23	569-571	by	_
3-24	572-582	reductions	_
3-25	583-585	in	_
3-26	586-588	DA	_
3-27	589-601	transporters	_
3-28	602-603	,	_
3-29	604-608	D2/3	_
3-30	609-618	receptors	_
3-31	619-622	and	_
3-32	623-633	endogenous	_
3-33	634-636	DA	_
3-34	637-643	levels	_
3-35	644-645	.	_

4-1	646-653	However	_
4-2	654-655	,	_
4-3	656-660	only	_
4-4	661-662	a	_
4-5	663-670	limited	_
4-6	671-677	number	_
4-7	678-680	of	_
4-8	681-688	studies	_
4-9	689-693	have	_
4-10	694-706	investigated	_
4-11	707-710	the	_
4-12	711-718	effects	_
4-13	719-721	of	_
4-14	722-727	dAMPH	_
4-15	728-730	in	_
4-16	731-734	the	_
4-17	735-740	human	_
4-18	741-746	brain	_
4-19	747-748	.	_

5-1	749-751	We	_
5-2	752-756	used	_
5-3	757-758	a	_
5-4	759-770	combination	_
5-5	771-773	of	_
5-6	774-787	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-7	788-798	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-8	799-807	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-9	808-817	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-10	818-825	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-11	826-827	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-12	828-835	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-13	836-837	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-14	838-841	and	_
5-15	842-843	[	_
5-16	844-848	123I	_
5-17	849-850	]	_
5-18	851-855	IBZM	_
5-19	856-869	single-photon	_
5-20	870-878	emission	_
5-21	879-887	computed	_
5-22	888-898	tomography	_
5-23	899-900	(	_
5-24	901-906	SPECT	_
5-25	907-908	)	_
5-26	909-910	(	_
5-27	911-913	to	_
5-28	914-920	assess	_
5-29	921-929	baseline	_
5-30	930-934	D2/3	_
5-31	935-943	receptor	_
5-32	944-951	binding	_
5-33	952-955	and	_
5-34	956-958	DA	_
5-35	959-966	release	_
5-36	967-968	)	_
5-37	969-971	in	_
5-38	972-974	15	_
5-39	975-987	recreational	_
5-40	988-992	AMPH	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-41	993-998	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-42	999-1002	and	_
5-43	1003-1005	20	_
5-44	1006-1013	matched	_
5-45	1014-1021	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-46	1022-1030	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-47	1031-1033	to	_
5-48	1034-1045	investigate	_
5-49	1046-1049	the	_
5-50	1050-1056	short-	_
5-51	1057-1058	,	_
5-52	1059-1062	and	_
5-53	1063-1072	long-term	_
5-54	1073-1080	effects	_
5-55	1081-1083	of	_
5-56	1084-1088	AMPH	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
5-57	1089-1095	before	_
5-58	1096-1099	and	_
5-59	1100-1105	after	_
5-60	1106-1108	an	_
5-61	1109-1114	acute	_
5-62	1115-1126	intravenous	_
5-63	1127-1136	challenge	_
5-64	1137-1141	with	_
5-65	1142-1147	dAMPH	_
5-66	1148-1149	.	_

6-1	1150-1152	We	_
6-2	1153-1158	found	_
6-3	1159-1163	that	_
6-4	1164-1169	acute	_
6-5	1170-1175	dAMPH	_
6-6	1176-1190	administration	_
6-7	1191-1198	reduced	_
6-8	1199-1209	functional	_
6-9	1210-1222	connectivity	_
6-10	1223-1225	in	_
6-11	1226-1229	the	_
6-12	1230-1255	cortico-striatal-thalamic	_
6-13	1256-1263	network	_
6-14	1264-1265	.	_

7-1	1266-1279	dAMPH-induced	_
7-2	1280-1282	DA	_
7-3	1283-1290	release	_
7-4	1291-1292	,	_
7-5	1293-1296	but	_
7-6	1297-1300	not	_
7-7	1301-1303	DA	_
7-8	1304-1308	D2/3	_
7-9	1309-1317	receptor	_
7-10	1318-1325	binding	_
7-11	1326-1327	,	_
7-12	1328-1331	was	_
7-13	1332-1342	positively	_
7-14	1343-1353	associated	_
7-15	1354-1358	with	_
7-16	1359-1371	connectivity	_
7-17	1372-1379	changes	_
7-18	1380-1382	in	_
7-19	1383-1387	this	_
7-20	1388-1395	network	_
7-21	1396-1397	.	_

8-1	1398-1400	In	_
8-2	1401-1409	addition	_
8-3	1410-1411	,	_
8-4	1412-1417	acute	_
8-5	1418-1423	dAMPH	_
8-6	1424-1431	reduced	_
8-7	1432-1444	connectivity	_
8-8	1445-1447	in	_
8-9	1448-1455	default	_
8-10	1456-1460	mode	_
8-11	1461-1469	networks	_
8-12	1470-1473	and	_
8-13	1474-1501	salience-executive-networks	_
8-14	1502-1510	networks	_
8-15	1511-1513	in	_
8-16	1514-1518	both	_
8-17	1519-1525	groups	_
8-18	1526-1527	.	_

9-1	1528-1530	In	_
9-2	1531-1539	contrast	_
9-3	1540-1542	to	_
9-4	1543-1546	our	_
9-5	1547-1557	hypothesis	_
9-6	1558-1559	,	_
9-7	1560-1562	no	_
9-8	1563-1574	significant	_
9-9	1575-1580	group	_
9-10	1581-1592	differences	_
9-11	1593-1597	were	_
9-12	1598-1603	found	_
9-13	1604-1606	in	_
9-14	1607-1610	any	_
9-15	1611-1613	of	_
9-16	1614-1617	the	_
9-17	1618-1625	rs-fMRI	_
9-18	1626-1634	networks	_
9-19	1635-1647	investigated	_
9-20	1648-1649	,	_
9-21	1650-1658	possibly	_
9-22	1659-1662	due	_
9-23	1663-1665	to	_
9-24	1666-1670	lack	_
9-25	1671-1673	of	_
9-26	1674-1685	sensitivity	_
9-27	1686-1688	or	_
9-28	1689-1701	compensatory	_
9-29	1702-1712	mechanisms	_
9-30	1713-1714	.	_

10-1	1715-1718	Our	_
10-2	1719-1727	findings	_
10-3	1728-1732	thus	_
10-4	1733-1740	support	_
10-5	1741-1744	the	_
10-6	1745-1748	use	_
10-7	1749-1751	of	_
10-8	1752-1761	ICA-based	_
10-9	1762-1775	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-10	1776-1786	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-11	1787-1799	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-12	1800-1802	as	_
10-13	1803-1804	a	_
10-14	1805-1809	tool	_
10-15	1810-1812	to	_
10-16	1813-1824	investigate	_
10-17	1825-1830	acute	_
10-18	1831-1832	,	_
10-19	1833-1836	but	_
10-20	1837-1840	not	_
10-21	1841-1848	chronic	_
10-22	1849-1850	,	_
10-23	1851-1862	alterations	_
10-24	1863-1870	induced	_
10-25	1871-1873	by	_
10-26	1874-1879	dAMPH	_
10-27	1880-1882	on	_
10-28	1883-1895	dopaminergic	_
10-29	1896-1906	processing	_
10-30	1907-1909	in	_
10-31	1910-1913	the	_
10-32	1914-1922	striatum	_
10-33	1923-1924	.	_

11-1	1925-1932	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1933-1945	Participants	_
11-3	1946-1953	Sixteen	_
11-4	1954-1958	male	_
11-5	1959-1963	AMPH	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-6	1964-1969	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-7	1970-1973	and	_
11-8	1974-1978	age-	_
11-9	1979-1980	,	_
11-10	1981-1988	gender-	_
11-11	1989-1992	and	_
11-12	1993-2003	IQ-matched	_
11-13	2004-2012	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-14	2013-2017	were	_
11-15	2018-2027	recruited	_
11-16	2028-2035	through	_
11-17	2036-2042	online	_
11-18	2043-2057	advertisements	_
11-19	2058-2061	and	_
11-20	2062-2068	flyers	_
11-21	2069-2071	at	_
11-22	2072-2077	local	_
11-23	2078-2090	universities	_
11-24	2091-2094	and	_
11-25	2095-2103	colleges	_
11-26	2104-2105	.	_

12-1	2106-2115	Inclusion	_
12-2	2116-2124	criteria	_
12-3	2125-2128	for	_
12-4	2129-2132	the	_
12-5	2133-2137	AMPH	_
12-6	2138-2143	users	_
12-7	2144-2148	were	_
12-8	2149-2151	at	_
12-9	2152-2157	least	_
12-10	2158-2160	30	_
12-11	2161-2170	occasions	_
12-12	2171-2173	of	_
12-13	2174-2177	use	_
12-14	2178-2186	lifetime	_
12-15	2187-2188	.	_

13-1	2189-2192	The	_
13-2	2193-2195	20	_
13-3	2196-2203	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-4	2204-2212	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-5	2213-2217	were	_
13-6	2218-2225	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-7	2226-2236	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-8	2237-2241	with	_
13-9	2242-2244	no	_
13-10	2245-2258	self-reported	_
13-11	2259-2264	prior	_
13-12	2265-2268	use	_
13-13	2269-2271	of	_
13-14	2272-2276	AMPH	_
13-15	2277-2279	or	_
13-16	2280-2285	other	_
13-17	2286-2291	drugs	_
13-18	2292-2296	that	_
13-19	2297-2303	affect	_
13-20	2304-2307	the	_
13-21	2308-2320	dopaminergic	_
13-22	2321-2327	system	_
13-23	2328-2329	.	_

14-1	2330-2339	Exclusion	_
14-2	2340-2348	criteria	_
14-3	2349-2352	for	_
14-4	2353-2356	all	_
14-5	2357-2369	participants	_
14-6	2370-2374	were	_
14-7	2375-2376	a	_
14-8	2377-2384	history	_
14-9	2385-2387	of	_
14-10	2388-2389	a	_
14-11	2390-2397	chronic	_
14-12	2398-2410	neurological	_
14-13	2411-2413	or	_
14-14	2414-2425	psychiatric	_
14-15	2426-2434	disorder	_
14-16	2435-2436	,	_
14-17	2437-2443	family	_
14-18	2444-2451	history	_
14-19	2452-2454	of	_
14-20	2455-2461	sudden	_
14-21	2462-2467	heart	_
14-22	2468-2475	failure	_
14-23	2476-2477	,	_
14-24	2478-2485	current	_
14-25	2486-2489	use	_
14-26	2490-2492	of	_
14-27	2493-2505	psychoactive	_
14-28	2506-2516	medication	_
14-29	2517-2518	,	_
14-30	2519-2527	abnormal	_
14-31	2528-2545	electrocardiogram	_
14-32	2546-2547	(	_
14-33	2548-2551	ECG	_
14-34	2552-2553	)	_
14-35	2554-2555	,	_
14-36	2556-2564	positive	_
14-37	2565-2569	drug	_
14-38	2570-2576	screen	_
14-39	2577-2578	,	_
14-40	2579-2582	and	_
14-41	2583-2584	a	_
14-42	2585-2593	clinical	_
14-43	2594-2603	diagnosis	_
14-44	2604-2606	of	_
14-45	2607-2611	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
14-46	2612-2613	,	_
14-47	2614-2616	in	_
14-48	2617-2625	addition	_
14-49	2626-2628	to	_
14-50	2629-2636	smoking	_
14-51	2637-2641	more	_
14-52	2642-2646	than	_
14-53	2647-2649	15	_
14-54	2650-2660	cigarettes	_
14-55	2661-2664	per	_
14-56	2665-2668	day	_
14-57	2669-2670	,	_
14-58	2671-2679	drinking	_
14-59	2680-2684	more	_
14-60	2685-2689	than	_
14-61	2690-2692	30	_
14-62	2693-2702	alcoholic	_
14-63	2703-2712	beverages	_
14-64	2713-2716	per	_
14-65	2717-2721	week	_
14-66	2722-2723	,	_
14-67	2724-2727	and	_
14-68	2728-2745	contraindications	_
14-69	2746-2749	for	_
14-70	2750-2760	undergoing	_
14-71	2761-2763	an	_
14-72	2764-2767	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
14-73	2768-2772	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
14-74	2773-2774	(	_
14-75	2775-2778	e.g	_
14-76	2779-2780	.	_

15-1	2781-2794	ferromagnetic	_
15-2	2795-2804	fragments	_
15-3	2805-2806	)	_
15-4	2807-2809	or	_
15-5	2810-2813	the	_
15-6	2814-2819	SPECT	_
15-7	2820-2829	procedure	_
15-8	2830-2831	(	_
15-9	2832-2835	e.g	_
15-10	2836-2837	.	_

16-1	2838-2845	allergy	_
16-2	2846-2848	to	_
16-3	2849-2855	iodine	_
16-4	2856-2857	)	_
16-5	2858-2859	.	_

17-1	2860-2863	The	_
17-2	2864-2871	results	_
17-3	2872-2874	of	_
17-4	2875-2878	the	_
17-5	2879-2884	SPECT	_
17-6	2885-2890	study	_
17-7	2891-2893	in	_
17-8	2894-2898	this	_
17-9	2899-2905	cohort	_
17-10	2906-2909	are	_
17-11	2910-2914	more	_
17-12	2915-2926	elaborately	_
17-13	2927-2935	reported	_
17-14	2936-2945	elsewhere	_
17-15	2946-2947	(	_
17-16	2948-2957	Schrantee	_
17-17	2958-2960	et	_
17-18	2961-2963	al	_
17-19	2964-2965	.	_
17-20	2966-2967	)	_
17-21	2968-2969	.	_

18-1	2970-2982	Participants	_
18-2	2983-2989	agreed	_
18-3	2990-2992	to	_
18-4	2993-3000	abstain	_
18-5	3001-3005	from	_
18-6	3006-3013	smoking	_
18-7	3014-3015	,	_
18-8	3016-3024	caffeine	_
18-9	3025-3026	,	_
18-10	3027-3034	alcohol	_
18-11	3035-3038	and	_
18-12	3039-3047	cannabis	_
18-13	3048-3051	for	_
18-14	3052-3054	24	_
18-15	3055-3056	h	_
18-16	3057-3062	prior	_
18-17	3063-3064	,	_
18-18	3065-3068	and	_
18-19	3069-3072	for	_
18-20	3073-3078	other	_
18-21	3079-3084	drugs	_
18-22	3085-3086	(	_
18-23	3087-3096	including	_
18-24	3097-3101	AMPH	_
18-25	3102-3103	)	_
18-26	3104-3107	one	_
18-27	3108-3112	week	_
18-28	3113-3118	prior	_
18-29	3119-3121	to	_
18-30	3122-3125	the	_
18-31	3126-3137	assessments	_
18-32	3138-3139	.	_

19-1	3140-3148	Subjects	_
19-2	3149-3153	were	_
19-3	3154-3159	asked	_
19-4	3160-3162	on	_
19-5	3163-3166	the	_
19-6	3167-3170	day	_
19-7	3171-3173	of	_
19-8	3174-3177	the	_
19-9	3178-3182	scan	_
19-10	3183-3185	if	_
19-11	3186-3190	they	_
19-12	3191-3194	had	_
19-13	3195-3199	used	_
19-14	3200-3203	any	_
19-15	3204-3206	of	_
19-16	3207-3212	these	_
19-17	3213-3223	substances	_
19-18	3224-3226	in	_
19-19	3227-3230	the	_
19-20	3231-3235	past	_
19-21	3236-3239	two	_
19-22	3240-3245	weeks	_
19-23	3246-3247	.	_

20-1	3248-3250	We	_
20-2	3251-3259	verified	_
20-3	3260-3263	the	_
20-4	3264-3272	reported	_
20-5	3273-3277	drug	_
20-6	3278-3281	use	_
20-7	3282-3286	with	_
20-8	3287-3288	a	_
20-9	3289-3293	drug	_
20-10	3294-3300	screen	_
20-11	3301-3303	on	_
20-12	3304-3305	a	_
20-13	3306-3311	urine	_
20-14	3312-3318	sample	_
20-15	3319-3323	with	_
20-16	3324-3326	an	_
20-17	3327-3344	enzyme-multiplied	_
20-18	3345-3356	immunoassay	_
20-19	3357-3360	for	_
20-20	3361-3373	amphetamines	_
20-21	3374-3375	,	_
20-22	3376-3383	cocaine	_
20-23	3384-3394	metabolite	_
20-24	3395-3396	,	_
20-25	3397-3404	opiates	_
20-26	3405-3408	and	_
20-27	3409-3418	marijuana	_
20-28	3419-3420	)	_
20-29	3421-3422	.	_

21-1	3423-3425	In	_
21-2	3426-3434	addition	_
21-3	3435-3436	,	_
21-4	3437-3438	a	_
21-5	3439-3447	detailed	_
21-6	3448-3452	drug	_
21-7	3453-3460	history	_
21-8	3461-3474	questionnaire	_
21-9	3475-3478	was	_
21-10	3479-3487	obtained	_
21-11	3488-3491	and	_
21-12	3492-3500	subjects	_
21-13	3501-3507	filled	_
21-14	3508-3510	in	_
21-15	3511-3514	the	_
21-16	3515-3519	drug	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-17	3520-3523	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-18	3524-3533	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-19	3534-3548	identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-20	3549-3553	test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-21	3554-3555	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-22	3556-3561	DUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-23	3562-3563	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
21-24	3564-3566	to	_
21-25	3567-3573	assess	_
21-26	3574-3583	substance	_
21-27	3584-3594	dependence	_
21-28	3595-3596	(	_
21-29	3597-3603	Voluse	_
21-30	3604-3606	et	_
21-31	3607-3609	al	_
21-32	3610-3611	.	_
21-33	3612-3613	)	_
21-34	3614-3615	.	_

22-1	3616-3619	The	_
22-2	3620-3625	Dutch	_
22-3	3626-3633	version	_
22-4	3634-3636	of	_
22-5	3637-3640	the	_
22-6	3641-3649	National	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-7	3650-3655	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-8	3656-3663	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-9	3664-3668	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-10	3669-3670	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-11	3671-3675	DART	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-12	3676-3678	IQ	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-13	3679-3680	)	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
22-14	3681-3684	was	_
22-15	3685-3694	conducted	_
22-16	3695-3697	as	_
22-17	3698-3700	an	_
22-18	3701-3709	estimate	_
22-19	3710-3712	of	_
22-20	3713-3719	verbal	_
22-21	3720-3732	intelligence	_
22-22	3733-3734	(	_
22-23	3735-3742	Schmand	_
22-24	3743-3745	et	_
22-25	3746-3748	al	_
22-26	3749-3750	.	_
22-27	3751-3752	)	_
22-28	3753-3754	.	_

23-1	3755-3758	One	_
23-2	3759-3770	participant	_
23-3	3771-3773	in	_
23-4	3774-3777	the	_
23-5	3778-3782	AMPH	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
23-6	3783-3788	group	_
23-7	3789-3795	showed	_
23-8	3796-3797	a	_
23-9	3798-3806	positive	_
23-10	3807-3811	drug	_
23-11	3812-3818	screen	_
23-12	3819-3822	and	_
23-13	3823-3826	was	_
23-14	3827-3836	therefore	_
23-15	3837-3845	excluded	_
23-16	3846-3847	,	_
23-17	3848-3850	so	_
23-18	3851-3854	the	_
23-19	3855-3863	analyses	_
23-20	3864-3868	were	_
23-21	3869-3878	performed	_
23-22	3879-3881	on	_
23-23	3882-3884	20	_
23-24	3885-3893	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
23-25	3894-3897	and	_
23-26	3898-3900	15	_
23-27	3901-3905	AMPH	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
23-28	3906-3911	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
23-29	3912-3913	.	_

24-1	3914-3917	The	_
24-2	3918-3925	medical	_
24-3	3926-3932	ethics	_
24-4	3933-3942	committee	_
24-5	3943-3945	of	_
24-6	3946-3949	the	_
24-7	3950-3958	Academic	_
24-8	3959-3966	Medical	_
24-9	3967-3973	Center	_
24-10	3974-3976	in	_
24-11	3977-3986	Amsterdam	_
24-12	3987-3995	approved	_
24-13	3996-3999	the	_
24-14	4000-4005	study	_
24-15	4006-4016	procedures	_
24-16	4017-4020	and	_
24-17	4021-4028	written	_
24-18	4029-4037	informed	_
24-19	4038-4045	consent	_
24-20	4046-4049	was	_
24-21	4050-4058	obtained	_
24-22	4059-4063	from	_
24-23	4064-4067	all	_
24-24	4068-4076	subjects	_
24-25	4077-4080	and	_
24-26	4081-4088	carried	_
24-27	4089-4092	out	_
24-28	4093-4095	in	_
24-29	4096-4106	accordance	_
24-30	4107-4111	with	_
24-31	4112-4115	the	_
24-32	4116-4125	standards	_
24-33	4126-4128	of	_
24-34	4129-4132	the	_
24-35	4133-4144	Declaration	_
24-36	4145-4147	of	_
24-37	4148-4156	Helsinki	_
24-38	4157-4158	.	_

25-1	4159-4165	Design	_
25-2	4166-4178	Participants	_
25-3	4179-4183	were	_
25-4	4184-4191	invited	_
25-5	4192-4194	to	_
25-6	4195-4198	the	_
25-7	4199-4207	hospital	_
25-8	4208-4211	for	_
25-9	4212-4215	two	_
25-10	4216-4221	study	_
25-11	4222-4228	visits	_
25-12	4229-4230	.	_

26-1	4231-4233	On	_
26-2	4234-4237	one	_
26-3	4238-4241	day	_
26-4	4242-4246	they	_
26-5	4247-4256	underwent	_
26-6	4257-4260	the	_
26-7	4261-4266	SPECT	http://maven.renci.org/NeuroBridge/neurobridge#SinglePhotonImaging
26-8	4267-4271	scan	http://maven.renci.org/NeuroBridge/neurobridge#SinglePhotonImaging
26-9	4272-4276	with	_
26-10	4277-4282	dAMPH	_
26-11	4283-4297	administration	_
26-12	4298-4301	and	_
26-13	4302-4304	on	_
26-14	4305-4308	the	_
26-15	4309-4314	other	_
26-16	4315-4318	day	_
26-17	4319-4323	they	_
26-18	4324-4333	underwent	_
26-19	4334-4337	the	_
26-20	4338-4341	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
26-21	4342-4346	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
26-22	4347-4351	with	_
26-23	4352-4357	dAMPH	_
26-24	4358-4372	administration	_
26-25	4373-4374	.	_

27-1	4375-4378	The	_
27-2	4379-4385	visits	_
27-3	4386-4390	were	_
27-4	4391-4393	at	_
27-5	4394-4399	least	_
27-6	4400-4403	one	_
27-7	4404-4408	week	_
27-8	4409-4414	apart	_
27-9	4415-4417	to	_
27-10	4418-4423	allow	_
27-11	4424-4428	drug	_
27-12	4429-4436	washout	_
27-13	4437-4440	and	_
27-14	4441-4445	were	_
27-15	4446-4461	counterbalanced	_
27-16	4462-4468	within	_
27-17	4469-4475	groups	_
27-18	4476-4477	.	_

28-1	4478-4482	Both	_
28-2	4483-4486	for	_
28-3	4487-4490	the	_
28-4	4491-4494	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-5	4495-4498	and	_
28-6	4499-4502	the	_
28-7	4503-4508	SPECT	http://maven.renci.org/NeuroBridge/neurobridge#SinglePhotonImaging
28-8	4509-4513	scan	http://maven.renci.org/NeuroBridge/neurobridge#SinglePhotonImaging
28-9	4514-4515	,	_
28-10	4516-4517	a	_
28-11	4518-4525	cannula	_
28-12	4526-4529	was	_
28-13	4530-4538	inserted	_
28-14	4539-4541	in	_
28-15	4542-4545	the	_
28-16	4546-4557	antecubital	_
28-17	4558-4562	vein	_
28-18	4563-4570	through	_
28-19	4571-4576	which	_
28-20	4577-4580	the	_
28-21	4581-4586	dAMPH	_
28-22	4587-4590	was	_
28-23	4591-4603	administered	_
28-24	4604-4605	(	_
28-25	4606-4609	0.3	_
28-26	4610-4615	mg/kg	_
28-27	4616-4617	)	_
28-28	4618-4624	during	_
28-29	4625-4626	2	_
28-30	4627-4630	min	_
28-31	4631-4632	,	_
28-32	4633-4641	followed	_
28-33	4642-4644	by	_
28-34	4645-4647	15	_
28-35	4648-4650	ml	_
28-36	4651-4657	saline	_
28-37	4658-4660	to	_
28-38	4661-4666	flush	_
28-39	4667-4668	(	_
28-40	4669-4672	Fig	_
28-41	4673-4674	.	_

29-1	4675-4676	1	_
29-2	4677-4678	)	_
29-3	4679-4680	.	_

30-1	4681-4686	SPECT	_
30-2	4687-4698	acquisition	_
30-3	4699-4702	and	_
30-4	4703-4711	analysis	_
30-5	4712-4716	Each	_
30-6	4717-4724	subject	_
30-7	4725-4733	received	_
30-8	4734-4736	an	_
30-9	4737-4748	intravenous	_
30-10	4749-4758	injection	_
30-11	4759-4761	of	_
30-12	4762-4765	180	_
30-13	4766-4769	MBq	_
30-14	4770-4771	[	_
30-15	4772-4776	123I	_
30-16	4777-4778	]	_
30-17	4779-4783	IBZM	_
30-18	4784-4785	(	_
30-19	4786-4788	80	_
30-20	4789-4792	MBq	_
30-21	4793-4798	bolus	_
30-22	4799-4807	followed	_
30-23	4808-4810	by	_
30-24	4811-4819	constant	_
30-25	4820-4828	infusion	_
30-26	4829-4831	of	_
30-27	4832-4834	20	_
30-28	4835-4838	MBq	_
30-29	4839-4842	for	_
30-30	4843-4844	5	_
30-31	4845-4856	consecutive	_
30-32	4857-4862	hours	_
30-33	4863-4864	)	_
30-34	4865-4866	.	_

31-1	4867-4875	Subjects	_
31-2	4876-4885	underwent	_
31-3	4886-4889	two	_
31-4	4890-4891	[	_
31-5	4892-4896	123I	_
31-6	4897-4898	]	_
31-7	4899-4903	IBZM	_
31-8	4904-4909	SPECT	_
31-9	4910-4915	scans	_
31-10	4916-4917	,	_
31-11	4918-4923	using	_
31-12	4924-4927	the	_
31-13	4928-4937	sustained	_
31-14	4938-4958	equilibrium/constant	_
31-15	4959-4967	infusion	_
31-16	4968-4977	technique	_
31-17	4978-4979	,	_
31-18	4980-4982	to	_
31-19	4983-4989	assess	_
31-20	4990-4998	baseline	_
31-21	4999-5007	striatal	_
31-22	5008-5010	DA	_
31-23	5011-5015	D2/3	_
31-24	5016-5024	receptor	_
31-25	5025-5037	availability	_
31-26	5038-5041	and	_
31-27	5042-5045	the	_
31-28	5046-5054	decrease	_
31-29	5055-5057	in	_
31-30	5058-5062	D2/3	_
31-31	5063-5071	receptor	_
31-32	5072-5079	binding	_
31-33	5080-5085	after	_
31-34	5086-5089	the	_
31-35	5090-5095	dAMPH	_
31-36	5096-5105	challenge	_
31-37	5106-5107	,	_
31-38	5108-5113	which	_
31-39	5114-5122	provides	_
31-40	5123-5125	an	_
31-41	5126-5131	index	_
31-42	5132-5134	of	_
31-43	5135-5137	DA	_
31-44	5138-5145	release	_
31-45	5146-5147	(	_
31-46	5148-5155	Kegeles	_
31-47	5156-5158	et	_
31-48	5159-5161	al	_
31-49	5162-5163	.	_
31-50	5164-5165	)	_
31-51	5166-5167	.	_

32-1	5168-5171	The	_
32-2	5172-5183	radioligand	_
32-3	5184-5185	[	_
32-4	5186-5190	123I	_
32-5	5191-5192	]	_
32-6	5193-5197	IBZM	_
32-7	5198-5199	,	_
32-8	5200-5205	which	_
32-9	5206-5211	binds	_
32-10	5212-5216	with	_
32-11	5217-5221	high	_
32-12	5222-5230	affinity	_
32-13	5231-5233	to	_
32-14	5234-5236	DA	_
32-15	5237-5241	D2/3	_
32-16	5242-5251	receptors	_
32-17	5252-5253	,	_
32-18	5254-5257	was	_
32-19	5258-5266	prepared	_
32-20	5267-5269	by	_
32-21	5270-5272	GE	_
32-22	5273-5283	Healthcare	_
32-23	5284-5285	(	_
32-24	5286-5295	Eindhoven	_
32-25	5296-5297	,	_
32-26	5298-5301	The	_
32-27	5302-5313	Netherlands	_
32-28	5314-5315	)	_
32-29	5316-5317	.	_

33-1	5318-5330	Participants	_
33-2	5331-5339	received	_
33-3	5340-5349	potassium	_
33-4	5350-5356	iodide	_
33-5	5357-5364	tablets	_
33-6	5365-5370	prior	_
33-7	5371-5373	to	_
33-8	5374-5377	the	_
33-9	5378-5383	SPECT	_
33-10	5384-5391	session	_
33-11	5392-5394	to	_
33-12	5395-5400	block	_
33-13	5401-5408	thyroid	_
33-14	5409-5415	uptake	_
33-15	5416-5418	of	_
33-16	5419-5423	free	_
33-17	5424-5435	radioactive	_
33-18	5436-5442	iodide	_
33-19	5443-5444	.	_

34-1	5445-5451	Images	_
34-2	5452-5456	were	_
34-3	5457-5465	acquired	_
34-4	5466-5468	on	_
34-5	5469-5470	a	_
34-6	5471-5486	brain-dedicated	_
34-7	5487-5492	SPECT	_
34-8	5493-5499	system	_
34-9	5500-5501	(	_
34-10	5502-5512	Neurofocus	_
34-11	5513-5516	810	_
34-12	5517-5518	,	_
34-13	5519-5523	Inc.	_
34-14	5524-5525	,	_
34-15	5526-5534	Medfield	_
34-16	5535-5536	,	_
34-17	5537-5550	Massachusetts	_
34-18	5551-5552	,	_
34-19	5553-5556	USA	_
34-20	5557-5558	)	_
34-21	5559-5563	with	_
34-22	5564-5567	the	_
34-23	5568-5577	following	_
34-24	5578-5588	parameters	_
34-25	5589-5590	:	_
34-26	5591-5597	matrix	_
34-27	5598-5599	:	_
34-28	5600-5602	64	_
34-29	5603-5604	×	_
34-30	5605-5607	64	_
34-31	5608-5609	,	_
34-32	5610-5616	energy	_
34-33	5617-5623	window	_
34-34	5624-5625	:	_
34-35	5626-5633	135–190	_
34-36	5634-5637	keV	_
34-37	5638-5639	,	_
34-38	5640-5645	slice	_
34-39	5646-5655	thickness	_
34-40	5656-5657	:	_
34-41	5658-5659	5	_
34-42	5660-5662	mm	_
34-43	5663-5664	,	_
34-44	5665-5676	acquisition	_
34-45	5677-5681	time	_
34-46	5682-5685	per	_
34-47	5686-5691	slice	_
34-48	5692-5693	:	_
34-49	5694-5697	300	_
34-50	5698-5699	s	_
34-51	5700-5701	,	_
34-52	5702-5708	number	_
34-53	5709-5711	of	_
34-54	5712-5718	slices	_
34-55	5719-5720	:	_
34-56	5721-5723	12	_
34-57	5724-5725	.	_

35-1	5726-5731	SPECT	_
35-2	5732-5738	images	_
35-3	5739-5743	were	_
35-4	5744-5753	corrected	_
35-5	5754-5757	for	_
35-6	5758-5769	attenuation	_
35-7	5770-5773	and	_
35-8	5774-5787	reconstructed	_
35-9	5788-5793	using	_
35-10	5794-5803	iterative	_
35-11	5804-5814	algorithms	_
35-12	5815-5816	,	_
35-13	5817-5819	as	_
35-14	5820-5827	earlier	_
35-15	5828-5837	described	_
35-16	5838-5839	(	_
35-17	5840-5845	Booij	_
35-18	5846-5848	et	_
35-19	5849-5851	al	_
35-20	5852-5853	.	_

36-1	5854-5855	;	_
36-2	5856-5860	Boot	_
36-3	5861-5863	et	_
36-4	5864-5866	al	_
36-5	5867-5868	.	_
36-6	5869-5870	)	_
36-7	5871-5872	.	_

37-1	5873-5880	Binding	_
37-2	5881-5890	potential	_
37-3	5891-5892	(	_
37-4	5893-5897	BPND	_
37-5	5898-5899	)	_
37-6	5900-5903	was	_
37-7	5904-5914	calculated	_
37-8	5915-5917	as	_
37-9	5918-5925	follows	_
37-10	5926-5927	:	_
37-11	5928-5929	(	_
37-12	5930-5934	mean	_
37-13	5935-5943	striatal	_
37-14	5944-5951	binding	_
37-15	5952-5953	–	_
37-16	5954-5958	mean	_
37-17	5959-5966	binding	_
37-18	5967-5976	occipital	_
37-19	5977-5983	cortex	_
37-20	5984-5985	)	_
37-21	5986-5991	/mean	_
37-22	5992-5999	binding	_
37-23	6000-6009	occipital	_
37-24	6010-6016	cortex	_
37-25	6017-6018	.	_

38-1	6019-6027	Standard	_
38-2	6028-6037	templates	_
38-3	6038-6042	with	_
38-4	6043-6048	fixed	_
38-5	6049-6053	ROIs	_
38-6	6054-6058	were	_
38-7	6059-6069	positioned	_
38-8	6070-6072	on	_
38-9	6073-6076	the	_
38-10	6077-6085	striatum	_
38-11	6086-6089	and	_
38-12	6090-6099	occipital	_
38-13	6100-6106	cortex	_
38-14	6107-6108	(	_
38-15	6109-6119	reflecting	_
38-16	6120-6132	non-specific	_
38-17	6133-6140	binding	_
38-18	6141-6142	)	_
38-19	6143-6144	,	_
38-20	6145-6147	as	_
38-21	6148-6155	earlier	_
38-22	6156-6165	described	_
38-23	6166-6167	(	_
38-24	6168-6173	Booij	_
38-25	6174-6176	et	_
38-26	6177-6179	al	_
38-27	6180-6181	.	_

39-1	6182-6183	;	_
39-2	6184-6188	Boot	_
39-3	6189-6191	et	_
39-4	6192-6194	al	_
39-5	6195-6196	.	_

40-1	6197-6198	;	_
40-2	6199-6204	Figee	_
40-3	6205-6207	et	_
40-4	6208-6210	al	_
40-5	6211-6212	.	_
40-6	6213-6214	)	_
40-7	6215-6216	.	_

41-1	6217-6230	dAMPH-induced	_
41-2	6231-6239	decrease	_
41-3	6240-6242	in	_
41-4	6243-6244	[	_
41-5	6245-6249	123I	_
41-6	6250-6251	]	_
41-7	6252-6256	IBZM	_
41-8	6257-6261	BPND	_
41-9	6262-6263	,	_
41-10	6264-6268	used	_
41-11	6269-6271	as	_
41-12	6272-6273	a	_
41-13	6274-6279	proxy	_
41-14	6280-6283	for	_
41-15	6284-6286	DA	_
41-16	6287-6294	release	_
41-17	6295-6296	,	_
41-18	6297-6300	was	_
41-19	6301-6310	expressed	_
41-20	6311-6313	as	_
41-21	6314-6315	a	_
41-22	6316-6317	%	_
41-23	6318-6320	of	_
41-24	6321-6324	the	_
41-25	6325-6334	pre-dAMPH	_
41-26	6335-6339	BPND	_
41-27	6340-6341	(	_
41-28	6342-6347	Booij	_
41-29	6348-6350	et	_
41-30	6351-6353	al	_
41-31	6354-6355	.	_
41-32	6356-6357	)	_
41-33	6358-6359	.	_

42-1	6360-6364	FMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-2	6365-6376	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
42-3	6377-6384	Imaging	_
42-4	6385-6388	was	_
42-5	6389-6398	performed	_
42-6	6399-6401	on	_
42-7	6402-6403	a	_
42-8	6404-6411	3-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
42-9	6412-6419	Ingenia	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
42-10	6420-6427	scanner	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
42-11	6428-6429	(	_
42-12	6430-6437	Philips	_
42-13	6438-6439	,	_
42-14	6440-6444	Best	_
42-15	6445-6446	,	_
42-16	6447-6450	The	_
42-17	6451-6462	Netherlands	_
42-18	6463-6464	)	_
42-19	6465-6473	equipped	_
42-20	6474-6478	with	_
42-21	6479-6480	a	_
42-22	6481-6491	16-channel	_
42-23	6492-6496	head	_
42-24	6497-6501	coil	_
42-25	6502-6503	.	_

43-1	6504-6505	A	_
43-2	6506-6517	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-3	6518-6528	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-4	6529-6533	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-5	6534-6537	was	_
43-6	6538-6546	acquired	_
43-7	6547-6550	for	_
43-8	6551-6563	registration	_
43-9	6564-6572	purposes	_
43-10	6573-6574	.	_

44-1	6575-6578	For	_
44-2	6579-6582	the	_
44-3	6583-6590	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-4	6591-6595	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-5	6596-6600	with	_
44-6	6601-6618	blood-oxygenation	_
44-7	6619-6634	level-dependent	_
44-8	6635-6636	(	http://maven.renci.org/NeuroBridge/neurobridge#Thing
44-9	6637-6641	BOLD	_
44-10	6642-6643	)	_
44-11	6644-6652	contrast	_
44-12	6653-6654	,	_
44-13	6655-6658	130	_
44-14	6659-6664	whole	_
44-15	6665-6670	brain	_
44-16	6671-6678	volumes	_
44-17	6679-6681	of	_
44-18	6682-6684	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-19	6685-6686	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-20	6687-6696	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-21	6697-6705	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-22	6706-6710	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-23	6711-6717	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-24	6718-6724	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-25	6725-6726	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-26	6727-6730	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-27	6731-6732	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-28	6733-6737	were	_
44-29	6738-6746	obtained	_
44-30	6747-6751	with	_
44-31	6752-6755	the	_
44-32	6756-6765	following	_
44-33	6766-6770	scan	_
44-34	6771-6781	parameters	_
44-35	6782-6783	:	_
44-36	6784-6789	TR/TE	_
44-37	6790-6797	2300/25	_
44-38	6798-6800	ms	_
44-39	6801-6802	;	_
44-40	6803-6807	flip	_
44-41	6808-6813	angle	_
44-42	6814-6817	80°	_
44-43	6818-6819	;	_
44-44	6820-6823	FOV	_
44-45	6824-6825	=	_
44-46	6826-6829	220	_
44-47	6830-6831	×	_
44-48	6832-6835	220	_
44-49	6836-6837	×	_
44-50	6838-6841	117	_
44-51	6842-6843	;	_
44-52	6844-6846	39	_
44-53	6847-6853	slices	_
44-54	6854-6855	;	_
44-55	6856-6861	voxel	_
44-56	6862-6866	size	_
44-57	6867-6870	2.3	_
44-58	6871-6872	×	_
44-59	6873-6876	2.3	_
44-60	6877-6878	×	_
44-61	6879-6880	3	_
44-62	6881-6883	mm	_
44-63	6884-6885	,	_
44-64	6886-6891	SENSE	_
44-65	6892-6895	2.4	_
44-66	6896-6897	.	_

45-1	6898-6901	The	_
45-2	6902-6910	subjects	_
45-3	6911-6920	underwent	_
45-4	6921-6924	the	_
45-5	6925-6932	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-6	6933-6937	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-7	6938-6944	before	_
45-8	6945-6950	dAMPH	_
45-9	6951-6965	administration	_
45-10	6966-6969	and	_
45-11	6970-6983	approximately	_
45-12	6984-6986	30	_
45-13	6987-6990	min	_
45-14	6991-7001	post-dAMPH	_
45-15	7002-7003	.	_

46-1	7004-7006	In	_
46-2	7007-7010	the	_
46-3	7011-7015	time	_
46-4	7016-7023	between	_
46-5	7024-7027	the	_
46-6	7028-7029	2	_
46-7	7030-7043	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-8	7044-7049	scans	_
46-9	7050-7053	the	_
46-10	7054-7062	subjects	_
46-11	7063-7072	underwent	_
46-12	7073-7075	an	_
46-13	7076-7084	arterial	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
46-14	7085-7089	spin	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-15	7090-7098	labeling	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-16	7099-7100	(	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-17	7101-7104	ASL	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-18	7105-7106	)	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-19	7107-7111	scan	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
46-20	7112-7113	.	_

47-1	7114-7122	Subjects	_
47-2	7123-7127	were	_
47-3	7128-7138	instructed	_
47-4	7139-7141	to	_
47-5	7142-7146	keep	_
47-6	7147-7152	their	_
47-7	7153-7157	eyes	_
47-8	7158-7162	open	_
47-9	7163-7166	and	_
47-10	7167-7170	let	_
47-11	7171-7176	their	_
47-12	7177-7181	mind	_
47-13	7182-7188	wander	_
47-14	7189-7190	.	_

48-1	7191-7195	FMRI	_
48-2	7196-7204	analysis	_
48-3	7205-7208	ICA	_
48-4	7209-7216	network	_
48-5	7217-7227	extraction	_
48-6	7228-7231	and	_
48-7	7232-7244	connectivity	_
48-8	7245-7253	analyses	_
48-9	7254-7261	RS-fMRI	_
48-10	7262-7266	data	_
48-11	7267-7271	were	_
48-12	7272-7284	preprocessed	_
48-13	7285-7290	using	_
48-14	7291-7296	tools	_
48-15	7297-7301	from	_
48-16	7302-7305	the	_
48-17	7306-7311	FMRIB	_
48-18	7312-7320	Software	_
48-19	7321-7328	Library	_
48-20	7329-7330	(	_
48-21	7331-7336	Smith	_
48-22	7337-7339	et	_
48-23	7340-7342	al	_
48-24	7343-7344	.	_
48-25	7345-7346	)	_
48-26	7347-7348	.	_

49-1	7349-7354	Brain	_
49-2	7355-7361	tissue	_
49-3	7362-7365	was	_
49-4	7366-7375	extracted	_
49-5	7376-7379	for	_
49-6	7380-7384	both	_
49-7	7385-7395	anatomical	_
49-8	7396-7399	and	_
49-9	7400-7410	functional	_
49-10	7411-7417	images	_
49-11	7418-7423	using	_
49-12	7424-7427	the	_
49-13	7428-7433	brain	_
49-14	7434-7444	extraction	_
49-15	7445-7449	tool	_
49-16	7450-7451	(	_
49-17	7452-7455	BET	_
49-18	7456-7457	)	_
49-19	7458-7459	.	_

50-1	7460-7470	Functional	_
50-2	7471-7475	data	_
50-3	7476-7480	were	_
50-4	7481-7487	motion	_
50-5	7488-7497	corrected	_
50-6	7498-7499	,	_
50-7	7500-7509	spatially	_
50-8	7510-7518	smoothed	_
50-9	7519-7523	with	_
50-10	7524-7525	a	_
50-11	7526-7534	Gaussian	_
50-12	7535-7541	kernel	_
50-13	7542-7544	of	_
50-14	7545-7546	5	_
50-15	7547-7549	mm	_
50-16	7550-7554	FWHM	_
50-17	7555-7558	and	_
50-18	7559-7568	high-pass	_
50-19	7569-7577	temporal	_
50-20	7578-7587	filtering	_
50-21	7588-7590	at	_
50-22	7591-7594	0.1	_
50-23	7595-7597	Hz	_
50-24	7598-7601	was	_
50-25	7602-7609	applied	_
50-26	7610-7611	.	_

51-1	7612-7614	In	_
51-2	7615-7623	addition	_
51-3	7624-7625	,	_
51-4	7626-7632	single	_
51-5	7633-7640	session	_
51-6	7641-7652	independent	_
51-7	7653-7662	component	_
51-8	7663-7671	analysis	_
51-9	7672-7673	(	_
51-10	7674-7677	ICA	_
51-11	7678-7679	)	_
51-12	7680-7683	was	_
51-13	7684-7693	performed	_
51-14	7694-7696	to	_
51-15	7697-7704	prepare	_
51-16	7705-7708	the	_
51-17	7709-7713	data	_
51-18	7714-7717	for	_
51-19	7718-7723	FMRIB	_
51-20	7724-7725	’	_
51-21	7726-7727	s	_
51-22	7728-7737	ICA-based	_
51-23	7738-7749	Xnoiseifier	_
51-24	7750-7751	(	_
51-25	7752-7755	FIX	_
51-26	7756-7757	)	_
51-27	7758-7759	(	_
51-28	7760-7769	Griffanti	_
51-29	7770-7772	et	_
51-30	7773-7775	al	_
51-31	7776-7777	.	_

52-1	7778-7779	;	_
52-2	7780-7796	Salimi-Khorshidi	_
52-3	7797-7799	et	_
52-4	7800-7802	al	_
52-5	7803-7804	.	_
52-6	7805-7806	)	_

53-1	7807-7809	to	_
53-2	7810-7817	denoise	_
53-3	7818-7821	the	_
53-4	7822-7829	rs-fMRI	_
53-5	7830-7834	data	_
53-6	7835-7836	.	_

54-1	7837-7842	Prior	_
54-2	7843-7845	to	_
54-3	7846-7854	analysis	_
54-4	7855-7856	,	_
54-5	7857-7860	all	_
54-6	7861-7871	functional	_
54-7	7872-7878	images	_
54-8	7879-7883	were	_
54-9	7884-7889	first	_
54-10	7890-7900	registered	_
54-11	7901-7903	to	_
54-12	7904-7907	the	_
54-13	7908-7923	high-resolution	_
54-14	7924-7934	anatomical	_
54-15	7935-7940	image	_
54-16	7941-7942	(	_
54-17	7943-7946	BBR	_
54-18	7947-7948	)	_
54-19	7949-7952	and	_
54-20	7953-7965	subsequently	_
54-21	7966-7968	to	_
54-22	7969-7977	standard	_
54-23	7978-7990	stereotactic	_
54-24	7991-7996	space	_
54-25	7997-7998	(	_
54-26	7999-8000	2	_
54-27	8001-8003	mm	_
54-28	8004-8005	,	_
54-29	8006-8012	MNI152	_
54-30	8013-8021	template	_
54-31	8022-8023	;	_
54-32	8024-8032	Montreal	_
54-33	8033-8045	Neurological	_
54-34	8046-8055	Institute	_
54-35	8056-8057	,	_
54-36	8058-8066	Montreal	_
54-37	8067-8069	QC	_
54-38	8070-8071	)	_
54-39	8072-8077	using	_
54-40	8078-8084	affine	_
54-41	8085-8099	transformation	_
54-42	8100-8101	.	_

55-1	8102-8114	Subsequently	_
55-2	8115-8116	,	_
55-3	8117-8120	the	_
55-4	8121-8129	denoised	_
55-5	8130-8134	data	_
55-6	8135-8139	were	_
55-7	8140-8144	used	_
55-8	8145-8147	to	_
55-9	8148-8159	investigate	_
55-10	8160-8162	RS	_
55-11	8163-8171	networks	_
55-12	8172-8174	in	_
55-13	8175-8178	our	_
55-14	8179-8185	groups	_
55-15	8186-8191	using	_
55-16	8192-8205	multi-session	_
55-17	8206-8209	ICA	_
55-18	8210-8214	with	_
55-19	8215-8223	temporal	_
55-20	8224-8237	concatenation	_
55-21	8238-8239	(	_
55-22	8240-8242	as	_
55-23	8243-8254	implemented	_
55-24	8255-8257	in	_
55-25	8258-8261	FSL	_
55-26	8262-8269	MELODIC	_
55-27	8270-8271	,	_
55-28	8272-8280	Beckmann	_
55-29	8281-8284	and	_
55-30	8285-8290	Smith	_
55-31	8291-8292	)	_
55-32	8293-8294	.	_

56-1	8295-8304	Automatic	_
56-2	8305-8319	dimensionality	_
56-3	8320-8330	estimation	_
56-4	8331-8334	was	_
56-5	8335-8339	used	_
56-6	8340-8342	to	_
56-7	8343-8351	estimate	_
56-8	8352-8355	the	_
56-9	8356-8362	number	_
56-10	8363-8365	of	_
56-11	8366-8376	components	_
56-12	8377-8386	extracted	_
56-13	8387-8388	.	_

57-1	8389-8391	In	_
57-2	8392-8400	addition	_
57-3	8401-8403	to	_
57-4	8404-8407	the	_
57-5	8408-8411	CST	_
57-6	8412-8419	network	_
57-7	8420-8421	,	_
57-8	8422-8424	we	_
57-9	8425-8433	explored	_
57-10	8434-8435	7	_
57-11	8436-8444	networks	_
57-12	8445-8448	for	_
57-13	8449-8456	further	_
57-14	8457-8465	analysis	_
57-15	8466-8471	based	_
57-16	8472-8474	on	_
57-17	8475-8480	their	_
57-18	8481-8492	involvement	_
57-19	8493-8495	in	_
57-20	8496-8508	higher-order	_
57-21	8509-8518	cognitive	_
57-22	8519-8528	processes	_
57-23	8529-8535	and/or	_
57-24	8536-8544	DA-ergic	_
57-25	8545-8553	function	_
57-26	8554-8556	or	_
57-27	8557-8570	DA-associated	_
57-28	8571-8582	pathologies	_
57-29	8583-8584	(	_
57-30	8585-8589	Cole	_
57-31	8590-8592	et	_
57-32	8593-8595	al	_
57-33	8596-8597	.	_
57-34	8598-8599	)	_
57-35	8600-8601	.	_

58-1	8602-8607	These	_
58-2	8608-8616	networks	_
58-3	8617-8621	will	_
58-4	8622-8624	be	_
58-5	8625-8633	referred	_
58-6	8634-8636	to	_
58-7	8637-8639	as	_
58-8	8640-8643	the	_
58-9	8644-8645	(	_
58-10	8646-8647	i	_
58-11	8648-8649	)	_
58-12	8650-8666	left-lateralised	_
58-13	8667-8682	fronto-parietal	_
58-14	8683-8690	network	_
58-15	8691-8692	(	_
58-16	8693-8697	lFPN	_
58-17	8698-8699	)	_
58-18	8700-8701	(	_
58-19	8702-8704	ii	_
58-20	8705-8706	)	_
58-21	8707-8724	right-lateralised	_
58-22	8725-8740	fronto-parietal	_
58-23	8741-8748	network	_
58-24	8749-8750	(	_
58-25	8751-8755	rFPN	_
58-26	8756-8757	)	_
58-27	8758-8759	(	_
58-28	8760-8763	iii	_
58-29	8764-8765	)	_
58-30	8766-8774	anterior	_
58-31	8775-8782	default	_
58-32	8783-8787	mode	_
58-33	8788-8795	network	_
58-34	8796-8797	(	_
58-35	8798-8802	aDMN	_
58-36	8803-8804	)	_
58-37	8805-8806	(	_
58-38	8807-8809	iv	_
58-39	8810-8811	)	_
58-40	8812-8821	posterior	_
58-41	8822-8829	default	_
58-42	8830-8834	mode	_
58-43	8835-8842	network	_
58-44	8843-8844	(	_
58-45	8845-8849	pDMN	_
58-46	8850-8851	)	_
58-47	8852-8853	(	_
58-48	8854-8855	v	_
58-49	8856-8857	)	_
58-50	8858-8865	ventral	_
58-51	8866-8873	default	_
58-52	8874-8878	mode	_
58-53	8879-8886	network	_
58-54	8887-8888	(	_
58-55	8889-8893	vDMN	_
58-56	8894-8895	)	_
58-57	8896-8897	(	_
58-58	8898-8900	vi	_
58-59	8901-8902	)	_
58-60	8903-8911	inferior	_
58-61	8912-8930	salience/executive	_
58-62	8931-8938	network	_
58-63	8939-8940	(	_
58-64	8941-8945	iSEN	_
58-65	8946-8947	)	_
58-66	8948-8949	(	_
58-67	8950-8953	vii	_
58-68	8954-8955	)	_
58-69	8956-8962	dorsal	_
58-70	8963-8981	salience/executive	_
58-71	8982-8989	network	_
58-72	8990-8991	(	_
58-73	8992-8996	dSEN	_
58-74	8997-8998	)	_
58-75	8999-9000	.	_

59-1	9001-9004	For	_
59-2	9005-9010	those	_
59-3	9011-9016	eight	_
59-4	9017-9025	networks	_
59-5	9026-9027	,	_
59-6	9028-9031	the	_
59-7	9032-9035	set	_
59-8	9036-9038	of	_
59-9	9039-9046	spatial	_
59-10	9047-9051	maps	_
59-11	9052-9056	from	_
59-12	9057-9060	the	_
59-13	9061-9074	group-average	_
59-14	9075-9083	analysis	_
59-15	9084-9087	was	_
59-16	9088-9092	used	_
59-17	9093-9095	to	_
59-18	9096-9104	generate	_
59-19	9105-9121	subject-specific	_
59-20	9122-9130	versions	_
59-21	9131-9133	of	_
59-22	9134-9137	the	_
59-23	9138-9145	spatial	_
59-24	9146-9150	maps	_
59-25	9151-9152	,	_
59-26	9153-9156	and	_
59-27	9157-9167	associated	_
59-28	9168-9179	time-series	_
59-29	9180-9181	,	_
59-30	9182-9187	using	_
59-31	9188-9192	dual	_
59-32	9193-9203	regression	_
59-33	9204-9208	with	_
59-34	9209-9217	variance	_
59-35	9218-9231	normalization	_
59-36	9232-9233	(	_
59-37	9234-9242	Beckmann	_
59-38	9243-9245	et	_
59-39	9246-9248	al	_
59-40	9249-9250	.	_

60-1	9251-9252	;	_
60-2	9253-9262	Filippini	_
60-3	9263-9265	et	_
60-4	9266-9268	al	_
60-5	9269-9270	.	_
60-6	9271-9272	)	_
60-7	9273-9274	.	_

61-1	9275-9280	First	_
61-2	9281-9282	,	_
61-3	9283-9286	for	_
61-4	9287-9291	each	_
61-5	9292-9299	subject	_
61-6	9300-9301	,	_
61-7	9302-9305	the	_
61-8	9306-9319	group-average	_
61-9	9320-9323	set	_
61-10	9324-9326	of	_
61-11	9327-9334	spatial	_
61-12	9335-9339	maps	_
61-13	9340-9343	was	_
61-14	9344-9353	regressed	_
61-15	9354-9355	(	_
61-16	9356-9358	as	_
61-17	9359-9366	spatial	_
61-18	9367-9377	regressors	_
61-19	9378-9380	in	_
61-20	9381-9382	a	_
61-21	9383-9391	multiple	_
61-22	9392-9402	regression	_
61-23	9403-9404	)	_
61-24	9405-9409	into	_
61-25	9410-9413	the	_
61-26	9414-9421	subject	_
61-27	9422-9423	’	_
61-28	9424-9425	s	_
61-29	9426-9428	4D	_
61-30	9429-9439	space-time	_
61-31	9440-9447	dataset	_
61-32	9448-9449	.	_

62-1	9450-9454	This	_
62-2	9455-9462	results	_
62-3	9463-9465	in	_
62-4	9466-9467	a	_
62-5	9468-9471	set	_
62-6	9472-9474	of	_
62-7	9475-9491	subject-specific	_
62-8	9492-9503	time-series	_
62-9	9504-9505	,	_
62-10	9506-9509	one	_
62-11	9510-9513	per	_
62-12	9514-9525	group-level	_
62-13	9526-9533	spatial	_
62-14	9534-9537	map	_
62-15	9538-9539	.	_

63-1	9540-9544	Next	_
63-2	9545-9546	,	_
63-3	9547-9552	those	_
63-4	9553-9564	time-series	_
63-5	9565-9569	were	_
63-6	9570-9579	regressed	_
63-7	9580-9581	(	_
63-8	9582-9584	as	_
63-9	9585-9593	temporal	_
63-10	9594-9604	regressors	_
63-11	9605-9606	,	_
63-12	9607-9612	again	_
63-13	9613-9615	in	_
63-14	9616-9617	a	_
63-15	9618-9626	multiple	_
63-16	9627-9637	regression	_
63-17	9638-9639	)	_
63-18	9640-9644	into	_
63-19	9645-9648	the	_
63-20	9649-9653	same	_
63-21	9654-9656	4D	_
63-22	9657-9664	dataset	_
63-23	9665-9666	,	_
63-24	9667-9676	resulting	_
63-25	9677-9679	in	_
63-26	9680-9681	a	_
63-27	9682-9685	set	_
63-28	9686-9688	of	_
63-29	9689-9705	subject-specific	_
63-30	9706-9713	spatial	_
63-31	9714-9718	maps	_
63-32	9719-9720	,	_
63-33	9721-9724	one	_
63-34	9725-9728	per	_
63-35	9729-9740	group-level	_
63-36	9741-9748	spatial	_
63-37	9749-9752	map	_
63-38	9753-9754	.	_

64-1	9755-9757	To	_
64-2	9758-9764	assess	_
64-3	9765-9773	baseline	_
64-4	9774-9779	group	_
64-5	9780-9791	differences	_
64-6	9792-9793	,	_
64-7	9794-9797	the	_
64-8	9798-9800	4D	_
64-9	9801-9806	files	_
64-10	9807-9810	for	_
64-11	9811-9815	each	_
64-12	9816-9823	network	_
64-13	9824-9828	were	_
64-14	9829-9833	then	_
64-15	9834-9842	analyzed	_
64-16	9843-9848	using	_
64-17	9849-9863	non-parametric	_
64-18	9864-9875	permutation	_
64-19	9876-9883	testing	_
64-20	9884-9885	(	_
64-21	9886-9890	5000	_
64-22	9891-9903	permutations	_
64-23	9904-9905	)	_
64-24	9906-9910	with	_
64-25	9911-9912	a	_
64-26	9913-9923	two-sample	_
64-27	9924-9930	t-test	_
64-28	9931-9936	using	_
64-29	9937-9940	the	_
64-30	9941-9944	FSL	_
64-31	9945-9954	Randomise	_
64-32	9955-9959	tool	_
64-33	9960-9961	(	_
64-34	9962-9969	Winkler	_
64-35	9970-9972	et	_
64-36	9973-9975	al	_
64-37	9976-9977	.	_
64-38	9978-9979	)	_
64-39	9980-9981	.	_

65-1	9982-9984	To	_
65-2	9985-9991	assess	_
65-3	9992-9995	the	_
65-4	9996-10002	effect	_
65-5	10003-10005	of	_
65-6	10006-10010	drug	_
65-7	10011-10014	and	_
65-8	10015-10018	the	_
65-9	10019-10030	interaction	_
65-10	10031-10037	effect	_
65-11	10038-10040	of	_
65-12	10041-10045	drug	_
65-13	10046-10049	and	_
65-14	10050-10055	group	_
65-15	10056-10057	,	_
65-16	10058-10060	we	_
65-17	10061-10071	calculated	_
65-18	10072-10082	difference	_
65-19	10083-10089	values	_
65-20	10090-10092	of	_
65-21	10093-10096	the	_
65-22	10097-10106	parameter	_
65-23	10107-10116	estimates	_
65-24	10117-10123	within	_
65-25	10124-10132	subjects	_
65-26	10133-10138	first	_
65-27	10139-10144	using	_
65-28	10145-10153	fslmaths	_
65-29	10154-10155	,	_
65-30	10156-10159	and	_
65-31	10160-10164	then	_
65-32	10165-10174	performed	_
65-33	10175-10176	a	_
65-34	10177-10187	one-sample	_
65-35	10188-10194	t-test	_
65-36	10195-10198	and	_
65-37	10199-10200	a	_
65-38	10201-10211	two-sample	_
65-39	10212-10218	t-test	_
65-40	10219-10231	respectively	_
65-41	10232-10233	,	_
65-42	10234-10239	again	_
65-43	10240-10245	using	_
65-44	10246-10255	Randomise	_
65-45	10256-10257	.	_

66-1	10258-10261	All	_
66-2	10262-10270	analyses	_
66-3	10271-10275	were	_
66-4	10276-10285	initially	_
66-5	10286-10297	thresholded	_
66-6	10298-10300	at	_
66-7	10301-10308	p-value	_
66-8	10309-10310	<	_
66-9	10311-10315	0.05	_
66-10	10316-10320	with	_
66-11	10321-10322	a	_
66-12	10323-10329	family	_
66-13	10330-10334	wise	_
66-14	10335-10340	error	_
66-15	10341-10342	(	_
66-16	10343-10346	FWE	_
66-17	10347-10348	)	_
66-18	10349-10359	correction	_
66-19	10360-10365	using	_
66-20	10366-10375	threshold	_
66-21	10376-10380	free	_
66-22	10381-10388	cluster	_
66-23	10389-10400	enhancement	_
66-24	10401-10402	(	_
66-25	10403-10407	TFCE	_
66-26	10408-10409	)	_
66-27	10410-10411	(	_
66-28	10412-10417	Smith	_
66-29	10418-10421	and	_
66-30	10422-10429	Nichols	_
66-31	10430-10431	)	_
66-32	10432-10433	.	_

67-1	10434-10444	Comparison	_
67-2	10445-10447	of	_
67-3	10448-10455	changes	_
67-4	10456-10458	in	_
67-5	10459-10461	RS	_
67-6	10462-10464	FC	_
67-7	10465-10468	and	_
67-8	10469-10471	DA	_
67-9	10472-10479	release	_
67-10	10480-10483	The	_
67-11	10484-10486	4D	_
67-12	10487-10492	files	_
67-13	10493-10503	comprising	_
67-14	10504-10520	subject-specific	_
67-15	10521-10528	spatial	_
67-16	10529-10533	maps	_
67-17	10534-10536	of	_
67-18	10537-10546	voxelwise	_
67-19	10547-10559	connectivity	_
67-20	10560-10564	with	_
67-21	10565-10568	the	_
67-22	10569-10572	CST	_
67-23	10573-10577	that	_
67-24	10578-10582	were	_
67-25	10583-10591	obtained	_
67-26	10592-10596	from	_
67-27	10597-10600	the	_
67-28	10601-10605	dual	_
67-29	10606-10616	regression	_
67-30	10617-10625	analysis	_
67-31	10626-10627	,	_
67-32	10628-10632	were	_
67-33	10633-10637	used	_
67-34	10638-10640	to	_
67-35	10641-10647	assess	_
67-36	10648-10651	the	_
67-37	10652-10663	correlation	_
67-38	10664-10671	between	_
67-39	10672-10679	changes	_
67-40	10680-10682	in	_
67-41	10683-10685	RS	_
67-42	10686-10688	FC	_
67-43	10689-10692	and	_
67-44	10693-10701	striatal	_
67-45	10702-10704	DA	_
67-46	10705-10712	release	_
67-47	10713-10722	following	_
67-48	10723-10728	acute	_
67-49	10729-10734	dAMPH	_
67-50	10735-10749	administration	_
67-51	10750-10751	.	_

68-1	10752-10754	We	_
68-2	10755-10763	examined	_
68-3	10764-10776	specifically	_
68-4	10777-10781	this	_
68-5	10782-10789	network	_
68-6	10790-10797	because	_
68-7	10798-10800	it	_
68-8	10801-10813	incorporated	_
68-9	10814-10817	the	_
68-10	10818-10826	striatum	_
68-11	10827-10828	,	_
68-12	10829-10832	the	_
68-13	10833-10838	brain	_
68-14	10839-10845	region	_
68-15	10846-10848	in	_
68-16	10849-10854	which	_
68-17	10855-10857	we	_
68-18	10858-10866	measured	_
68-19	10867-10869	DA	_
68-20	10870-10877	release	_
68-21	10878-10882	with	_
68-22	10883-10888	SPECT	_
68-23	10889-10890	,	_
68-24	10891-10894	and	_
68-25	10895-10902	because	_
68-26	10903-10908	dAMPH	_
68-27	10909-10911	is	_
68-28	10912-10919	thought	_
68-29	10920-10922	to	_
68-30	10923-10928	exert	_
68-31	10929-10932	its	_
68-32	10933-10941	greatest	_
68-33	10942-10949	effects	_
68-34	10950-10952	in	_
68-35	10953-10956	the	_
68-36	10957-10962	basal	_
68-37	10963-10970	ganglia	_
68-38	10971-10972	(	_
68-39	10973-10976	due	_
68-40	10977-10979	to	_
68-41	10980-10983	its	_
68-42	10984-10991	intense	_
68-43	10992-11000	DA-ergic	_
68-44	11001-11006	input	_
68-45	11007-11008	)	_
68-46	11009-11010	.	_

69-1	11011-11012	A	_
69-2	11013-11021	striatal	_
69-3	11022-11026	mask	_
69-4	11027-11030	was	_
69-5	11031-11038	created	_
69-6	11039-11042	for	_
69-7	11043-11046	the	_
69-8	11047-11049	FC	_
69-9	11050-11053	map	_
69-10	11054-11059	using	_
69-11	11060-11063	the	_
69-12	11064-11067	MNI	_
69-13	11068-11078	structural	_
69-14	11079-11084	atlas	_
69-15	11085-11086	(	_
69-16	11087-11094	Collins	_
69-17	11095-11097	et	_
69-18	11098-11100	al	_
69-19	11101-11102	.	_
69-20	11103-11104	)	_
69-21	11105-11106	.	_

70-1	11107-11109	We	_
70-2	11110-11116	tested	_
70-3	11117-11124	whether	_
70-4	11125-11135	individual	_
70-5	11136-11147	differences	_
70-6	11148-11150	in	_
70-7	11151-11153	RS	_
70-8	11154-11156	FC	_
70-9	11157-11163	within	_
70-10	11164-11168	this	_
70-11	11169-11177	striatal	_
70-12	11178-11182	mask	_
70-13	11183-11187	were	_
70-14	11188-11201	significantly	_
70-15	11202-11212	positively	_
70-16	11213-11215	or	_
70-17	11216-11226	negatively	_
70-18	11227-11237	correlated	_
70-19	11238-11242	with	_
70-20	11243-11245	DA	_
70-21	11246-11253	release	_
70-22	11254-11256	as	_
70-23	11257-11265	measured	_
70-24	11266-11270	with	_
70-25	11271-11272	[	_
70-26	11273-11277	123I	_
70-27	11278-11279	]	_
70-28	11280-11284	IBZM	_
70-29	11285-11290	SPECT	_
70-30	11291-11297	within	_
70-31	11298-11301	the	_
70-32	11302-11306	same	_
70-33	11307-11315	striatal	_
70-34	11316-11320	mask	_
70-35	11321-11323	in	_
70-36	11324-11327	the	_
70-37	11328-11331	CST	_
70-38	11332-11337	using	_
70-39	11338-11347	voxelwise	_
70-40	11348-11362	non-parametric	_
70-41	11363-11374	permutation	_
70-42	11375-11382	testing	_
70-43	11383-11385	as	_
70-44	11386-11397	implemented	_
70-45	11398-11400	in	_
70-46	11401-11410	Randomise	_
70-47	11411-11412	,	_
70-48	11413-11417	with	_
70-49	11418-11422	5000	_
70-50	11423-11435	permutations	_
70-51	11436-11439	and	_
70-52	11440-11441	5	_
70-53	11442-11444	mm	_
70-54	11445-11453	variance	_
70-55	11454-11463	smoothing	_
70-56	11464-11465	.	_

71-1	11466-11472	Voxels	_
71-2	11473-11477	were	_
71-3	11478-11488	considered	_
71-4	11489-11500	significant	_
71-5	11501-11503	at	_
71-6	11504-11511	p-value	_
71-7	11512-11513	<	_
71-8	11514-11518	0.05	_
71-9	11519-11523	with	_
71-10	11524-11525	a	_
71-11	11526-11529	FWE	_
71-12	11530-11540	correction	_
71-13	11541-11544	for	_
71-14	11545-11553	multiple	_
71-15	11554-11565	comparisons	_
71-16	11566-11571	using	_
71-17	11572-11576	TFCE	_
71-18	11577-11578	.	_

72-1	11579-11586	Effects	_
72-2	11587-11589	of	_
72-3	11590-11595	heart	_
72-4	11596-11600	rate	_
72-5	11601-11603	of	_
72-6	11604-11606	RS	_
72-7	11607-11609	FC	_
72-8	11610-11617	Changes	_
72-9	11618-11620	in	_
72-10	11621-11626	heart	_
72-11	11627-11631	rate	_
72-12	11632-11633	(	_
72-13	11634-11636	HR	_
72-14	11637-11638	)	_
72-15	11639-11643	have	_
72-16	11644-11648	been	_
72-17	11649-11654	found	_
72-18	11655-11657	to	_
72-19	11658-11667	influence	_
72-20	11668-11671	the	_
72-21	11672-11676	BOLD	_
72-22	11677-11683	signal	_
72-23	11684-11685	,	_
72-24	11686-11696	especially	_
72-25	11697-11701	near	_
72-26	11702-11707	large	_
72-27	11708-11715	vessels	_
72-28	11716-11717	,	_
72-29	11718-11721	and	_
72-30	11722-11737	consequentially	_
72-31	11738-11747	influence	_
72-32	11748-11750	FC	_
72-33	11751-11753	in	_
72-34	11754-11758	RSNs	_
72-35	11759-11760	(	_
72-36	11761-11775	Khalili-Mahani	_
72-37	11776-11778	et	_
72-38	11779-11781	al	_
72-39	11782-11783	.	_
72-40	11784-11785	)	_
72-41	11786-11787	.	_

73-1	11788-11800	Dopaminergic	_
73-2	11801-11806	drugs	_
73-3	11807-11811	such	_
73-4	11812-11814	as	_
73-5	11815-11820	dAMPH	_
73-6	11821-11824	are	_
73-7	11825-11830	known	_
73-8	11831-11833	to	_
73-9	11834-11842	increase	_
73-10	11843-11845	HR	_
73-11	11846-11849	and	_
73-12	11850-11855	blood	_
73-13	11856-11864	pressure	_
73-14	11865-11866	(	_
73-15	11867-11871	Lile	_
73-16	11872-11874	et	_
73-17	11875-11877	al	_
73-18	11878-11879	.	_
73-19	11880-11881	)	_
73-20	11882-11883	.	_

74-1	11884-11892	Although	_
74-2	11893-11896	FIX	_
74-3	11897-11905	denoises	_
74-4	11906-11909	the	_
74-5	11910-11914	data	_
74-6	11915-11918	and	_
74-7	11919-11926	thereby	_
74-8	11927-11934	removes	_
74-9	11935-11936	a	_
74-10	11937-11940	lot	_
74-11	11941-11943	of	_
74-12	11944-11957	physiological	_
74-13	11958-11967	variation	_
74-14	11968-11969	,	_
74-15	11970-11972	it	_
74-16	11973-11976	has	_
74-17	11977-11981	been	_
74-18	11982-11987	shown	_
74-19	11988-11992	that	_
74-20	11993-11998	areas	_
74-21	11999-12001	of	_
74-22	12002-12015	physiological	_
74-23	12016-12025	variation	_
74-24	12026-12029	can	_
74-25	12030-12037	overlap	_
74-26	12038-12042	with	_
74-27	12043-12046	our	_
74-28	12047-12051	RSNs	_
74-29	12052-12054	of	_
74-30	12055-12063	interest	_
74-31	12064-12065	.	_

75-1	12066-12075	Therefore	_
75-2	12076-12077	,	_
75-3	12078-12080	we	_
75-4	12081-12088	decided	_
75-5	12089-12091	to	_
75-6	12092-12098	repeat	_
75-7	12099-12102	our	_
75-8	12103-12111	analyses	_
75-9	12112-12117	using	_
75-10	12118-12125	average	_
75-11	12126-12128	HR	_
75-12	12129-12131	as	_
75-13	12132-12133	a	_
75-14	12134-12143	covariate	_
75-15	12144-12145	.	_

76-1	12146-12148	HR	_
76-2	12149-12152	was	_
76-3	12153-12162	monitored	_
76-4	12163-12169	during	_
76-5	12170-12173	the	_
76-6	12174-12177	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
76-7	12178-12182	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
76-8	12183-12190	session	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
76-9	12191-12196	using	_
76-10	12197-12198	a	_
76-11	12199-12205	4-lead	_
76-12	12206-12212	vector	_
76-13	12213-12223	cardiogram	_
76-14	12224-12225	(	http://maven.renci.org/NeuroBridge/neurobridge#Thing
76-15	12226-12229	VCG	_
76-16	12230-12231	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
76-17	12232-12238	signal	_
76-18	12239-12242	and	_
76-19	12243-12247	data	_
76-20	12248-12252	were	_
76-21	12253-12262	extracted	_
76-22	12263-12268	using	_
76-23	12269-12271	an	_
76-24	12272-12274	in	_
76-25	12275-12280	house	_
76-26	12281-12287	MATLAB	_
76-27	12288-12294	script	_
76-28	12295-12296	.	_

77-1	12297-12301	Five	_
77-2	12302-12304	of	_
77-3	12305-12308	our	_
77-4	12309-12311	HR	_
77-5	12312-12324	measurements	_
77-6	12325-12329	were	_
77-7	12330-12337	missing	_
77-8	12338-12341	and	_
77-9	12342-12346	they	_
77-10	12347-12351	were	_
77-11	12352-12359	imputed	_
77-12	12360-12364	with	_
77-13	12365-12368	the	_
77-14	12369-12376	average	_
77-15	12377-12379	HR	_
77-16	12380-12382	of	_
77-17	12383-12386	the	_
77-18	12387-12392	group	_
77-19	12393-12396	and	_
77-20	12397-12404	session	_
77-21	12405-12408	the	_
77-22	12409-12413	scan	_
77-23	12414-12422	belonged	_
77-24	12423-12425	to	_
77-25	12426-12427	.	_

